Circulating tumor DNA as prognostic markers of non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.

ABSTRACT:

Background

Circulating tumor DNA (ctDNA) has recently garnered attention as a promising prognostic biomarker in cancer patients. This review aimed to evaluate the prognostic significance of ctDNA in patients with non-small cell lung cancer (NSCLC) at different treatment timepoints.

Methods

A comprehensive search of PubMed, Web of Science, Embase, Cochrane Library, Scopus, ClinicalTrials.gov and World Health Organization International Clinical Trials Registry Platform (WHO-ICTRP) was performed covering the period from January 2016 to May 2022, with updates monitored until June 2024. Studies reporting ctDNA positivity versus negativity and associated survival outcomes were included. Hazard ratios (HRs) or risk ratios (RRs) were pooled using random-effects models for relapse-fr

SUBMITTER: Chen X 

PROVIDER: S-EPMC12775697 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature